Rationale and design of the ranolazine PH–RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension

INTRODUCTION: A major determining factor on outcomes in patients with pulmonary arterial hypertension (PAH) is right ventricular (RV) function. Ranolazine, which is currently approved for chronic stable angina, has been shown to improve RV function in an animal model and has been shown to be safe in...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yuchi, Forfia, Paul R, Vaidya, Anjali, Mazurek, Jeremy A, Park, Myung H, Ramani, Gautam, Chan, Stephen Y, Waxman, Aaron B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Pulmonary Vascular Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845423/
https://www.ncbi.nlm.nih.gov/pubmed/29531764
http://dx.doi.org/10.1136/openhrt-2017-000736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845423/
https://www.ncbi.nlm.nih.gov/pubmed/29531764
http://dx.doi.org/10.1136/openhrt-2017-000736

Ejemplares similares